Henry Schein (NASDAQ:HSIC) Director Philip Laskawy Sells 2,844 Shares of Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director Philip Laskawy sold 2,844 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the transaction, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Henry Schein Trading Down 3.2%

Shares of Henry Schein stock opened at $77.60 on Friday. The company has a market cap of $8.90 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29. The company’s fifty day simple moving average is $78.20 and its 200-day simple moving average is $72.57. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter last year, the firm earned $1.19 EPS. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

HSIC has been the topic of a number of recent analyst reports. Barclays initiated coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Leerink Partners boosted their target price on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research report on Tuesday, February 24th. Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Finally, Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Henry Schein currently has a consensus rating of “Hold” and an average target price of $85.58.

Institutional Investors Weigh In On Henry Schein

Large investors have recently modified their holdings of the stock. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC bought a new position in shares of Henry Schein in the fourth quarter worth approximately $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein in the fourth quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein during the fourth quarter valued at approximately $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.